The rhPTH (1-34), but not elcatonin, increases bone anabolic efficacy in postmenopausal women with osteoporosis

Experimental and Clinical Endocrinology and Diabetes

Volumn 120, Issue 6, 2012, Pages 361-366

  Zhang, L ^a   Yang, M ^a   Liu, D ^a   Guo, C ^a   Li, L ^a   Yang, G ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

bone turnover markers; osteoporosis; postmenopausal women; rhPTH

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; ELCATONIN; RECOMBINANT PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; OSSIFICATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RASH;

ADULT; AGED; AGED, 80 AND OVER; ANABOLIC AGENTS; BONE AND BONES; BONE DENSITY; CALCITONIN; FEMALE; HUMANS; METABOLISM; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84862175076     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0032-1309009     Document Type: Article

References (32)

1. Arisawa EA L, Brandao AA H, Almeida J D et al. Calcitonin in bone-guided regeneration of mandibles in ovariectomized rats: densitometric, histologic and histomorphometric analysis. Int J Oral Max Surg: 2008; 37 47 53 (Pubitemid 350216388)
2. Bellido T, Ali A A, Plotkin L I et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem: 2003; 278 50259 50272 (Pubitemid 37548867)
3. Bikle D D, Sakata T, Leary C et al. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res: 2002; 17 1570 1578
4. Body J J, Gaich G A, Scheele W H et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab: 2002; 87 4528 4535 (Pubitemid 35247036)
5. Brixen K T, Christensen P M, Ejersted C et al. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. Basic Clin Pharmacol Toxicol: 2004; 94 260 270 (Pubitemid 38954892)
6. Chaki O, Yoshikata I, Kikuchi R et al. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. J Bone Miner Res: 2000; 15 1537 1544 (Pubitemid 30484523)
7. Cheng X G, Yang D Z, Zhou Q et al. Age-related bone mineral density, bone loss rate, prevalence of osteoporosis, and reference database of women at multiple centers in China. J Clin Densitom: 2007; 10 276 284 (Pubitemid 47198535)
8. Chesnut C H, Majumdar S, Newitt D C et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: Results from the QUEST study. Journal of Bone and Mineral Research: 2005; 20 1548 1561 (Pubitemid 41243544)
9. Colpan L, Gur A, Cevik R et al. The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis. Maturitas: 2005; 51 246 253 (Pubitemid 40835945)
10. Cosman F, Nieves J, Woelfert L et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res: 2001; 16 925 931 (Pubitemid 32332303)
11. Dempster D W, Cosman F, Kurland E S et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res: 2001; 16 1846 1853 (Pubitemid 32911491)
12. Dempster D W, Cosman F, Parisien M et al. Anabolic actions of parathyroid hormone on bone. Endocr Rev: 1993; 14 690 709 (Pubitemid 24016657)
13. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med: 1998; 338 736 746 (Pubitemid 28115093)
14. Hodsman A B, Fraher L J, Watson P H et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab: 1997; 82 620 628 (Pubitemid 27068640)
15. Hodsman A B, Steer B M. Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for de novo bone formation on quiescent cancellous surfaces. Bone: 1993; 14 523 527 (Pubitemid 23175778)
16. Hwang J S, Tu S T, Yang T S et al. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int: 2006; 17 373 378
17. Kaufman J M, Orwoll E, Goemaere S et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA: 2005; 16 510 516
18. Lane N E, Sanchez S, Modin G W et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res: 2000; 15 944 951 (Pubitemid 30233419)
19. Liao E Y, Wu X P, Deng X G et al. Age-related bone mineral density, accumulated bone loss rate and prevalence of osteoporosis at multiple skeletal sites in chinese women. Osteoporos Int: 2002; 13 669 676
20. Lindsay R, Miller P, Pohl G et al. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA: 2009; 20 943 948
21. Lindsay R, Nieves J, Formica C et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet: 1997; 350 550 555 (Pubitemid 27348431)
22. Marcus R, Wang O, Satterwhite J et al. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research: 2003; 18 18 23 (Pubitemid 36008335)
23. Meunier P J, Vignot E, Garnero P et al. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporos Int: 1999; 10 330 336 (Pubitemid 29476199)
24. Neer R M, Arnaud C D, Zanchetta J R et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med: 2001; 344 1434 1441 (Pubitemid 32402100)
25. Pettway G J, Meganck J A, Koh A J et al. Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone: 2008; 42 806 818
26. Pi Y Z, Wu X P, Liu S P et al. Age-related changes in bone biochemical markers and their relationship with bone mineral density in normal Chinese women. J Bone Miner Metab: 2006; 24 380 385
27. Reeve J, Bradbeer J N, Arlot M et al. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses. Osteoporos Int: 1991; 1 162 170
28. Riggs B L, Melton L J 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone: 1995; 17 505S 511S
29. Rogers A, Hannon R A, Eastell R. Biochemical markers as predictors of rates of bone loss after menopause. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research: 2000; 15 1398 1404 (Pubitemid 30413874)
30. Silverman S L, Azria M. The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int: 2002; 13 858 867 (Pubitemid 35364786)
31. Zanchetta J R, Bogado C E, Ferretti J L et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res: 2003; 18 539 543 (Pubitemid 36241071)
32. Zhang X Z, Wang B, Yang J et al. randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China. Chin Med J (Engl): 2009; 122 2933 2938